Study points to promising chemoimmunotherapy strategy for aggressive stage III non-small cell lung cancer
A groundbreaking study from Dana-Farber Cancer Institute reveals that combining chemotherapy and immunotherapy before surgery can shrink aggressive stage III lung tumors, making surgery possible for patients previously deemed inoperable.
2 months ago
2 mins read
